DEFA14A: Annovis Bio CEO Addresses Stockholders Following Phase II/III Alzheimer's Study Results

Annovis Bio's CEO, Maria Maccecchini, issued a letter to stockholders addressing concerns and outlining next steps following the Phase II/III Alzheimer's study results.

Summary

• Annovis Bio's CEO, Maria Maccecchini, addressed stockholders following concerns about the Phase II/III Alzheimer's study results.
• The company aims to develop drugs for Alzheimer's and Parkinson's diseases.
• The Phase II/III study provided valuable information for an improved Phase III pivotal trial.
• Future trials will prescreen patients for plasma AD biomarkers and enroll only those with early and mild Alzheimer's (MMSE 21-28).
• Prior studies showed the highest level of improvement in patients with early Alzheimer's after buntanetap treatment.
• The goal of the Phase II/III trial was to learn about the breadth of the drug's efficacy and obtain information for a pivotal disease-modifying study.
• The company believes the FDA will accept buntanetap for symptomatic relief and allow them to continue with the next pivotal Phase III study for disease-modification.

Sentiment

Score: 4

Explanation: The document conveys a mixed sentiment. While the CEO expresses determination and outlines future plans, the acknowledgment of negative feedback and a drop in share price indicates underlying concerns.

Positives

• The Phase II/III study provided valuable information for an improved Phase III pivotal trial.
• The company believes the FDA will accept buntanetap for symptomatic relief.
• Previous studies showed the highest level of improvement in patients with early Alzheimer's after buntanetap treatment.

Negatives

• The Phase II/III study results were questioned and criticized, leading to a drop in the share price.
• The response in moderate AD patients (MMSE 14-20) was obscured by a high placebo effect.

Risks

• The company acknowledges risks and uncertainties that may cause actual results to differ materially from forward-looking statements.
• These risks include patient enrollment, the effectiveness of buntanetap, and the timing and results of clinical trials.

Future Outlook

The company plans to conduct an improved Phase III pivotal trial, focusing on patients with early and mild Alzheimer's, and believes the FDA will allow them to continue with the next pivotal Phase III study for disease-modification.

Management Comments

• The last few days have been very difficult.
• I received a lot of emails and phone calls that often expressed anger, uncertainty, and disappointment.
• Additionally, our results were questioned and criticized.
• We are determined to develop a drug that treats Alzheimers (AD) and Parkinsons diseases (PD) and makes the life of the afflicted people and their caretakers easier.
• In science, results are often less than perfect, but they pave the way for a better plan when designing and executing the next steps.

Industry Context

The announcement reflects the challenges and complexities inherent in developing effective treatments for neurodegenerative diseases like Alzheimer's and Parkinson's, where clinical trial outcomes can be variable and subject to scrutiny.

Stakeholder Impact

• Shareholders experienced a drop in share price due to concerns about the Phase II/III study results.
• The company aims to improve the lives of people afflicted with Alzheimer's and Parkinson's diseases and their caretakers.

Next Steps

• Prescreen patients for plasma AD biomarkers to confirm the diagnosis.
• Enroll only patients with early and mild Alzheimer's (MMSE 21-28) in future trials.
• Continue with the next pivotal Phase III study for disease-modification.

Key Dates

Keywords

Annovis Bio, Alzheimer's Disease, Buntanetap, Clinical Trial, Phase II/III, Neurodegenerative Diseases, Parkinson's Disease